AstraZeneca Stock - Analyst debates fair value after recent pullback

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 13:47 CET. Details in the imprint.

AstraZeneca (US6549022043) stands once again at the center of a valuation debate. Analyst commentary this week has revisited the stock’s fair value after a recent pullback and renewed discussion of pipeline potential and pricing risk.

What recent analysis highlights

Recent coverage from Simply Wall St argues that AstraZeneca shares on the London Stock Exchange could be about 20.2% undervalued versus an estimated fair value around GBP 164.85 and a latest closing price near GBP 131.54. The analysis hosted on Yahoo Finance summarizes this view.

The same analysis points out that the stock has declined roughly 5% over the past month and more over three months, which has sharpened the discussion about whether the current level adequately reflects AstraZeneca’s growth prospects and risk profile. According to the Simply Wall St summary, the market may be underestimating parts of the late-stage pipeline.

Long-term business model in focus

On a Saturday, the lens naturally shifts to the long-term picture: AstraZeneca positions itself as a research-driven biopharma group with a focus on oncology, cardiovascular and metabolic diseases, and respiratory and immunology therapies. The company’s own overview of therapy areas outlines this focus.

Management has emphasized in recent years that future growth should stem from an expanding oncology portfolio, next-generation cardiovascular and renal drugs, and scaling of rare disease assets, with productivity gains in R&D and manufacturing intended to support margins over time.

The product behind the stock

AstraZeneca makes its money primarily from patented prescription medicines, with flagship oncology drugs such as Tagrisso and Imfinzi, cardiovascular therapy Farxiga and respiratory treatment Symbicort among the key revenue drivers alongside newer launches in rare diseases and immunology.

Where the stock trades today

The shares of AstraZeneca (US6549022043) trade on Nasdaq in New York at $174.93 as of 06/20/2026, 13:47 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.